Skip to main content

Advertisement

Table 1 Identification of differentially expressed proteins between ASt and nASt by iTRAQ-based proteomics

From: Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study

No Protein information Peptide detection Fold changea
Rec. protein name UniprotID Rec. symbol MW Peptide score Peptide coverage Unique peptides ASt/nASt ASt/NC nASt/NC
1 Polymeric immunoglobulin receptor P01833 PIGR 83 29.78 1.05 1 3.628 3.002 n.d.
2 Serum amyloid A protein 1 P02735 SAA1 14 409.61 54.1 6 3.201 3.023 n.d.
3 Heat shock 60 kDa protein 1 P10809 HSPD1 61 65.56 3.66 1 2.313 n.d. n.d.
4 Orosomucoid P02763 ORM1 24 72.88 18.91 3 1.884 1.233 n.d.
5 SCAN domain containing 3 Q6R2W3 ZNF452 152 13.59 0.38 1 1.629 1.424 n.d.
6 DEAD box polypeptide 41 Q9UJV9 DDX41 70 32.35 0.96 1 1.479 n.d. n.d.
7 Serpin peptidase inhibitor, antityripsin member 3 P01011 SERPINA3 48 160.91 10.4 4 1.464 n.d. n.d.
8 Serum amyloid A-4, constitutive P35542 SAA4 15 103.51 21.54 3 1.452 n.d. n.d.
9 Fatty acid synthase P49327 FASN 273 30.66 0.52 1 1.417 2.308 1.675
10 Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 ITIH3 100 139.48 5.84 5 1.364 n.d. n.d.
11 Alpha-1B-glycoprotein P04217 A1BG 54 157.16 13.74 6 1.348 n.d. n.d.
12 Lipopolysaccharide binding protein P18428 LBP 53 437.6 22.04 9 1.336 1.793 1.345
13 Retinol binding protein 4 P02753 RBP4 23 48.89 4.98 1 1.276 n.d. n.d.
14 Ribosomal protein S6 P62753 RPS6 29 22.91 6.83 1 1.229 n.d. n.d.
15 Secreted phosphoprotein 2, 24 kDa Q13103 SPP24 24 22.13 4.27 1 1.22 1.208 n.d.
16 Fibrinogen gamma chain P02679 FGG 52 1307.66 63.58 29 1.212 n.d. n.d.
17 Complement factor H-related protein 1 Q03591 FHR1 38 465.78 36.97 2 1.211 n.d. n.d.
18 Fibrinogen alpha chain P02671 FGA 95 2078.11 46.88 40 1.207 n.d. n.d.
19 Hemopexin P02790 HPX 52 245.23 22.73 8 1.204 n.d. n.d.
20 von Willebrand factor P04275 VWF 309 343.44 4.41 11 0.816 n.d. n.d.
21 Keratin 2 P35908 KRT2 65 288.46 11.58 6 0.814 0.723 n.d.
22 Pregnancy-zone protein P20742 PZP 164 422.01 10.86 11 0.803 n.d. n.d.
23 Apolipoprotein E P02649 APOE 36 1149.96 66.25 22 0.786 n.d. n.d.
24 Thrombospondin 1 P07996 THBS1 129 112.25 4.79 4 0.779 0.709 0.825
25 Gelsolin P06396 GSN 86 225.78 11.64 6 0.762 n.d. n.d.
26 Insulin-like growth factor-binding protein 3 P17936 IBP3 32 25.36 5.84 1 0.758 n.d. n.d.
27 Extracellular matrix protein 1 Q16610 ECM1 61 365.78 22.41 9 0.736 n.d. n.d.
28 Annexin 1 P04083 ANXA1 39 31.01 4.34 1 0.726 n.d. n.d.
29 Hyaluronoglucosaminidase 1 Q12794 HYAL1 48 40.73 5.52 1 0.657 0.716 n.d.
30 Serpin F1 P36955 PEDF 46 33.05 2.15 1 0.586 n.d. n.d.
31 Annexin A2 pseudogene 2 A6NMY6 ANXA2P2 39 30.15 4.72 1 0.357 n.d. n.d.
  1. aFor a candidate protein, the fold change (ratio) of at least or more than 1.2, and at least or less than 0.80 in plasma content was considered and reported as up- and downregulation, respectively. ASt, Abnormal Savda type tumours; nASt, non-Abnormal Savda type tumours; NC, normal controls; n.d. no difference (fold change of less than 1.2 or more than 0.8); ASt/nASt, fold change of all differentially expressed proteins between ASt and nASt; ASt/NC or nASt/NC, fold change of the same proteins between ASt and NC or nASt and NC as those differentially expressed in ASt/nASt.